Abstract
B cell-specific Moloney murine leukemia virus integration site 1 (Bmi1) was identified as a biomarker of cancer stem cells, and over-expression of Bmi1 might enhance tumor aggressive clinical behavior in gastric cancer (GC). Our aim of this meta-analysis is to investigate the prognostic role and clinicopathological differences of Bmi1 in GC patients. A total of 6 studies up to September 2014 were included in our study. Our results showed that there were no relationships between Bmi1 expression and the gender (pooled OR=0.87, 95%CI=0.66-1.14, P=0.319, fixed effect), age (pooled OR=1.22, 95%CI=0.95-1.59, P=0.126, fixed effect) and differentiation (pooled OR=1.15, 95%CI=0.71-1.86, P=0.582, random effect) in GC patients. But high Bmi1 expression was significantly correlated with the clinical stage (pooled OR=3.04, 95%CI=1.31-7.07, P=0.010, random effect), tumor size (pooled OR=2.01, 95%CI=1.14-3.55, P=0.016, random effect), T classification (pooled OR=2.79, 95%CI=1.94-4.03, P<0.001, fixed effect), lymph node metastasis (pooled OR=2.24, 95%CI=1.47-3.39, P<0.001, random effect) and distant metastasis (pooled OR=5.05, 95%CI=1.29-19.70, P=0.020, random effect), and led to a poor overall survival (OS) in GC patients (RR=3.38, 95%CI=2.43-4.69, P<0.001, fixed effect). These findings suggested that Bmi1 might serve as a novel and effective prognostic biomarker in GC, and could be a promising emerging molecular target in GC therapy.
Keywords: Bmi1, gastric cancer, meta-analysis, prognosis.
Anti-Cancer Agents in Medicinal Chemistry
Title:Prognostic Value and Clinicopathological Differences of Bmi1 in Gastric Cancer: A Meta-analysis
Volume: 16 Issue: 4
Author(s): Bin Yuan, Hong Zhao, Xiaofeng Xue, Jin Zhou, Xu Wang, Ye Han, Lifeng Zhang, Xiaobo Guo and Qiaoming Zhi
Affiliation:
Keywords: Bmi1, gastric cancer, meta-analysis, prognosis.
Abstract: B cell-specific Moloney murine leukemia virus integration site 1 (Bmi1) was identified as a biomarker of cancer stem cells, and over-expression of Bmi1 might enhance tumor aggressive clinical behavior in gastric cancer (GC). Our aim of this meta-analysis is to investigate the prognostic role and clinicopathological differences of Bmi1 in GC patients. A total of 6 studies up to September 2014 were included in our study. Our results showed that there were no relationships between Bmi1 expression and the gender (pooled OR=0.87, 95%CI=0.66-1.14, P=0.319, fixed effect), age (pooled OR=1.22, 95%CI=0.95-1.59, P=0.126, fixed effect) and differentiation (pooled OR=1.15, 95%CI=0.71-1.86, P=0.582, random effect) in GC patients. But high Bmi1 expression was significantly correlated with the clinical stage (pooled OR=3.04, 95%CI=1.31-7.07, P=0.010, random effect), tumor size (pooled OR=2.01, 95%CI=1.14-3.55, P=0.016, random effect), T classification (pooled OR=2.79, 95%CI=1.94-4.03, P<0.001, fixed effect), lymph node metastasis (pooled OR=2.24, 95%CI=1.47-3.39, P<0.001, random effect) and distant metastasis (pooled OR=5.05, 95%CI=1.29-19.70, P=0.020, random effect), and led to a poor overall survival (OS) in GC patients (RR=3.38, 95%CI=2.43-4.69, P<0.001, fixed effect). These findings suggested that Bmi1 might serve as a novel and effective prognostic biomarker in GC, and could be a promising emerging molecular target in GC therapy.
Export Options
About this article
Cite this article as:
Yuan Bin, Zhao Hong, Xue Xiaofeng, Zhou Jin, Wang Xu, Han Ye, Zhang Lifeng, Guo Xiaobo and Zhi Qiaoming, Prognostic Value and Clinicopathological Differences of Bmi1 in Gastric Cancer: A Meta-analysis, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (4) . https://dx.doi.org/10.2174/1871520615666150507120801
DOI https://dx.doi.org/10.2174/1871520615666150507120801 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Topotecan and Irinotecan in the Treatment of Pediatric Solid Tumors
Current Pediatric Reviews Left-Right Asymmetry in Embryonic Development and Breast Cancer: Common Molecular Determinants?
Current Medicinal Chemistry Trimethylamine: Metabolic, Pharmacokinetic and Safety Aspects
Current Drug Metabolism Mechanisms Underlying Chemopreventive Effects of Flavonoids via Multiple Signaling Nodes within Nrf2-ARE and AhR-XRE Gene Regulatory Networks
Current Chemical Biology Neurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance
Current Medicinal Chemistry Synthesis and Biological Activities of Substituted Benzoxazepine: A Review
Mini-Reviews in Organic Chemistry Is the Epithelial-to-Mesenchymal Transition Clinically Relevant for the Cancer Patient?
Current Pharmaceutical Biotechnology Preparation and Characterization of Bifunctional Nanoparticles of Vitamin E TPGS-emulsified PLGA-PEG-FOL Containing Deferasirox
Nanoscience & Nanotechnology-Asia Mutations in MicroRNA Genes and Their Binding Sites are Infrequently Associated with Human Colorectal Cancer in the Kashmiri Population
MicroRNA Phage Display Applications for Molecular Imaging
Current Pharmaceutical Biotechnology Soft Matter Assemblies as Nanomedicine Platforms for Cancer Chemotherapy: A Journey from Market Products Towards Novel Approaches
Current Topics in Medicinal Chemistry The Uses of Dimedone for the Synthesis of Thiophene, Thiazole and Annulated Derivatives with Antitumor, Pim-1 Kinase Inhibitions, PAINS Evaluations and Molecular Docking
Anti-Cancer Agents in Medicinal Chemistry Cell Division Cycle 25 (Cdc25) Phosphatase Inhibitors as Antitumor Agents
Drug Design Reviews - Online (Discontinued) The Role of Matrix Metalloproteinase Inhibitors in Ischemia-Reperfusion Injury in the Liver
Current Pharmaceutical Design Inventions Designed to Enhance Drug Delivery Across Epithelial and Endothelial Cells Through the Paracellular Pathway
Recent Patents on Drug Delivery & Formulation MicroRNAs in Esophageal Adenocarcinoma: Functional Significance and Potential for the Development of New Molecular Disease Markers
Current Pharmaceutical Design Exploiting Protein Phosphatase Inhibitors Based on Cantharidin Analogues for Cancer Drug Discovery
Mini-Reviews in Medicinal Chemistry An Overview of Natural Plant Products in the Treatment of Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry A Missed Proteome in Living Organisms: A Hyppo System
Current Proteomics Enhancing Oral Bioavailability of Methylnaltrexone Using an Emulsion Formulation
Letters in Drug Design & Discovery